Emerald Advisers’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-100,844
| Closed | -$4.64M | – | 247 |
|
|
2017
Q2 | $4.64M | Sell |
100,844
-205,026
| -67% | -$9.43M | 0.19% | 114 |
|
|
2017
Q1 | $13.2M | Sell |
305,870
-8,777
| -3% | -$380K | 0.54% | 74 |
|
|
2016
Q4 | $12.2M | Buy |
314,647
+57,818
| +23% | +$2.24M | 0.52% | 78 |
|
|
2016
Q3 | $13M | Buy |
256,829
+8,710
| +4% | +$441K | 0.58% | 66 |
|
|
2016
Q2 | $11.3M | Sell |
248,119
-65,425
| -21% | -$2.97M | 0.54% | 63 |
|
|
2016
Q1 | $12.4M | Buy |
313,544
+10,337
| +3% | +$409K | 0.6% | 62 |
|
|
2015
Q4 | $17.2M | Buy |
303,207
+36,180
| +14% | +$2.05M | 0.81% | 32 |
|
|
2015
Q3 | $10.6M | Sell |
267,027
-198,419
| -43% | -$7.9M | 0.55% | 61 |
|
|
2015
Q2 | $22.2M | Buy |
465,446
+3,193
| +0.7% | +$153K | 1.06% | 19 |
|
|
2015
Q1 | $17.5M | Sell |
462,253
-78,720
| -15% | -$2.97M | 0.88% | 26 |
|
|
2014
Q4 | $12.1M | Buy |
540,973
+206,790
| +62% | +$4.62M | 0.64% | 47 |
|
|
2014
Q3 | $5.24M | Buy |
334,183
+94,193
| +39% | +$1.48M | 0.31% | 105 |
|
|
2014
Q2 | $3.56M | Buy |
239,990
+1,580
| +0.7% | +$23.4K | 0.2% | 154 |
|
|
2014
Q1 | $3.84M | Buy |
+238,410
| New | +$3.84M | 0.22% | 143 |
|